Akcea Therapeutics is a commercial stage biopharmaceutical company developing and commercializing medicines to treat patients. Co. is focused on commercializing its approved therapies, TEGSEDI and WAYLIVRA. TEGSEDI is indicated to treat adults with the polyneuropathy caused by hereditary transthyretin-mediated amyloidosis, and has been approved and launched in the United States, the European Union, and Canada as well as approved in Brazil. WAYLIVRA is indicated as an adjunct to diet to treat adult patients with genetically confirmed familial chylomicronemia syndrome, who are at high risk for pancreatitis, for whom response to diet and triglyceride lowering therapy has been inadequate.
|
Free AKCA Email Alerts: Get SEC Filing Alerts Get Dividend Alerts |
Hold (2.00 out of 4) 100th percentile
(ranked higher than approx. 100% of all stocks covered)
Analysts' Target Price: AKCA Stock Forecast Based on Zacks ABR data; powered by Xignite |